Substituted anilines for treatment of animal diseases
View Patent ↗The invention provides compounds formula (I) and salts thereof: wherein R 1 -R 4 have any of the values defined in the specification. The compounds are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia. The compounds are also useful to lower IL-4, IL-5, or IL-15 levels in an animal.
1. A compound of formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is (C 3 -C 6 )alkoxy or (C 3 -C 6 )cycloalkyl-(C 1 -C 3 )alkoxy-;
R 2 is (C 3 -C 6 )alkyl or (C 3 -C 6 )alkoxy;
R 3 is (C 1 -C 6 )alkyl;
R 4 is phenyl, substituted at the position para to the point of attachment to the nitrogen atom with a group —CO 2 R c , and further optionally substituted on a ring carbon atom with one or more substituents independently selected from the group consisting of halo, hydroxy, nitro, cyano, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )alkanoyloxy, —NR a R b , or (C 3 -C 6 )cycloalkyl, wherein each (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )alkanoyloxy, and (C 3 -C 6 )cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of oxo, halo, hydroxy, nitro, cyano, (C 1 -C 6 )alkoxy, and —NR a R b ;
R a is H or (C 1 -C 6 )alkyl;
R b is H or (C 1 -C 6 )alkyl; or
R a and R b , taken together with the nitrogen atom to which they are attached, form a ring selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, and morpholinyl; and
R c is H or (C 1 -C 6 )alkyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is 2-methylpropoxy or cyclopropylmethoxy.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is (C 3 -C 6 )alkyl.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is isopropyl.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is (C 3 -C 6 )alkoxy.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is isopropyl, isopropoxy, or 2-methylpropoxy.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is isopropoxy or 2-methylpropoxy.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is (C 1 -C 3 )alkyl.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is ethyl.
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is:
11. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
12. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising the compound of claim 12 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. The compound:
or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition comprising the compound of claim 14 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.